Skip to main content
Top
Published in: Diabetologia 10/2015

01-10-2015 | Article

Islet autoantibody phenotypes and incidence in children at increased risk for type 1 diabetes

Authors: Eleni Z. Giannopoulou, Christiane Winkler, Ruth Chmiel, Claudia Matzke, Marlon Scholz, Andreas Beyerlein, Peter Achenbach, Ezio Bonifacio, Anette-G. Ziegler

Published in: Diabetologia | Issue 10/2015

Login to get access

Abstract

Aims/hypothesis

Autoantibodies that precede type 1 diabetes frequently develop in early childhood and target distinct beta cell proteins. The aim of this study was to determine the heterogeneity of islet autoantibody development and fate.

Methods

The ages of development of insulin autoantibodies (IAA) and GAD autoantibodies (GADA), followed by multiple islet autoantibodies and progression to diabetes were examined in 2,441 children participating in two German birth cohorts.

Results

In 218 children who developed islet autoantibodies, the first islet autoantibody-positive sample was characterised by single IAA in 80 (37%), multiple islet autoantibodies in 68 (31%) and single GADA in 63 (29%) children. Of the children who were single antibody positive at seroconversion, 35 (44%) IAA-positive and 15 (24%) GADA-positive children developed multiple islet autoantibodies. Single persistent antibodies had heterogeneous affinities; GADA were also heterogeneous in their binding to N-terminally truncated GAD65 and in an ELISA. Progression to diabetes occurred in >50% of children within 10 years in all groups that developed multiple islet autoantibodies and in 44% of children with persistent single high-affinity IAA or persistent single GADA that were positive in both a radiobinding assay and ELISA. The earliest autoantibody development was seen in children with single IAA that progressed to multiple islet autoantibodies or in those with persistent high-affinity single IAA, with a sharp peak in incidence observed at age 9 months. The peak incidence occurred at age 2 years for children who underwent seroconversion directly to multiple islet autoantibodies and at 5 years for children who first seroconverted to GADA and subsequently developed other autoantibodies. Seroconversion to low-affinity IAA or persistent single GADA occurred at a low incidence after the age of 9 months.

Conclusions/interpretation

Children of different ages have differing susceptibilities to autoimmunisation against specific beta cell autoantigens.
Appendix
Available only for authorised users
Literature
2.
go back to reference Ziegler AG, Rewers M, Simell O et al (2013) Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 309:2473–2479CrossRefPubMed Ziegler AG, Rewers M, Simell O et al (2013) Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 309:2473–2479CrossRefPubMed
3.
go back to reference Ziegler AG, Bonifacio E, Babydiab-Babydiet Study Group (2012) Age-related islet autoantibody incidence in offspring of patients with type 1 diabetes. Diabetologia 55:1937–1993CrossRefPubMed Ziegler AG, Bonifacio E, Babydiab-Babydiet Study Group (2012) Age-related islet autoantibody incidence in offspring of patients with type 1 diabetes. Diabetologia 55:1937–1993CrossRefPubMed
4.
go back to reference Chmiel R, Giannopoulou EZ, Winkler C, Achenbach P, Ziegler AG, Bonifacio E (2015) Progression from single to multiple islet autoantibodies often occurs soon after seroconversion: implications for early screening. Diabetologia 58:411–413CrossRefPubMed Chmiel R, Giannopoulou EZ, Winkler C, Achenbach P, Ziegler AG, Bonifacio E (2015) Progression from single to multiple islet autoantibodies often occurs soon after seroconversion: implications for early screening. Diabetologia 58:411–413CrossRefPubMed
5.
go back to reference Mayr A, Schlosser M, Grober N et al (2007) GAD autoantibody affinity and epitope specificity identify distinct immunization profiles in children at risk for type 1 diabetes. Diabetes 56:1527–1533CrossRefPubMed Mayr A, Schlosser M, Grober N et al (2007) GAD autoantibody affinity and epitope specificity identify distinct immunization profiles in children at risk for type 1 diabetes. Diabetes 56:1527–1533CrossRefPubMed
6.
go back to reference Achenbach P, Koczwara K, Knopff A, Naserke H, Ziegler AG, Bonifacio E (2004) Mature high-affinity immune responses to (pro)insulin anticipate the autoimmune cascade that leads to type 1 diabetes. J Clin Invest 114:589–597PubMedCentralCrossRefPubMed Achenbach P, Koczwara K, Knopff A, Naserke H, Ziegler AG, Bonifacio E (2004) Mature high-affinity immune responses to (pro)insulin anticipate the autoimmune cascade that leads to type 1 diabetes. J Clin Invest 114:589–597PubMedCentralCrossRefPubMed
7.
go back to reference Ziegler AG, Hummel M, Schenker M, Bonifacio E (1999) Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study. Diabetes 48:460–468CrossRefPubMed Ziegler AG, Hummel M, Schenker M, Bonifacio E (1999) Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study. Diabetes 48:460–468CrossRefPubMed
8.
go back to reference Hummel S, Pflüger M, Hummel M, Bonifacio E, Ziegler AG (2011) Primary dietary intervention study to reduce the risk of islet autoimmunity in children at increased risk for type 1 diabetes: the BABYDIET study. Diabetes Care 34:1301–1305PubMedCentralCrossRefPubMed Hummel S, Pflüger M, Hummel M, Bonifacio E, Ziegler AG (2011) Primary dietary intervention study to reduce the risk of islet autoimmunity in children at increased risk for type 1 diabetes: the BABYDIET study. Diabetes Care 34:1301–1305PubMedCentralCrossRefPubMed
9.
go back to reference Lampasona V, Schlosser M, Mueller PW et al (2011) Diabetes antibody standardization program: first proficiency evaluation of assays for autoantibodies to zinc transporter 8. Clin Chem 57:1693–1702CrossRefPubMed Lampasona V, Schlosser M, Mueller PW et al (2011) Diabetes antibody standardization program: first proficiency evaluation of assays for autoantibodies to zinc transporter 8. Clin Chem 57:1693–1702CrossRefPubMed
10.
go back to reference Schlosser M, Mueller PW, Törn C, Bonifacio E, Bingley PJ, Participating Laboratories (2010) Diabetes antibody standardization program: evaluation of assays for insulin autoantibodies. Diabetologia 53:2611–2620CrossRefPubMed Schlosser M, Mueller PW, Törn C, Bonifacio E, Bingley PJ, Participating Laboratories (2010) Diabetes antibody standardization program: evaluation of assays for insulin autoantibodies. Diabetologia 53:2611–2620CrossRefPubMed
11.
go back to reference Törn C, Mueller PW, Schlosser M, Bonifacio E, Bingley PJ, Participating Laboratories (2008) Diabetes antibody standardization program: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2. Diabetologia 51:846–852CrossRefPubMed Törn C, Mueller PW, Schlosser M, Bonifacio E, Bingley PJ, Participating Laboratories (2008) Diabetes antibody standardization program: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2. Diabetologia 51:846–852CrossRefPubMed
12.
go back to reference Puavilai G, Chanprasertyotin S, Sriphrapradaeng A (1999) Diagnostic criteria for diabetes mellitus and other categories of glucose intolerance: 1997 criteria by the expert committee on the diagnosis and classification of diabetes mellitus (ADA), 1998 Acta Diabetol 123 WHO consultation criteria, and 1985 WHO criteria. World Health Organization. Diabetes Res Clin Pract 44:21–26CrossRefPubMed Puavilai G, Chanprasertyotin S, Sriphrapradaeng A (1999) Diagnostic criteria for diabetes mellitus and other categories of glucose intolerance: 1997 criteria by the expert committee on the diagnosis and classification of diabetes mellitus (ADA), 1998 Acta Diabetol 123 WHO consultation criteria, and 1985 WHO criteria. World Health Organization. Diabetes Res Clin Pract 44:21–26CrossRefPubMed
13.
go back to reference Schenker M, Hummel M, Ferber K et al (1999) Early expression and high prevalence of islet autoantibodies for DR3/4 heterozygous and DR4/4 homozygous offspring of parents with type I diabetes: the German BABYDIAB study. Diabetologia 42:671–677CrossRefPubMed Schenker M, Hummel M, Ferber K et al (1999) Early expression and high prevalence of islet autoantibodies for DR3/4 heterozygous and DR4/4 homozygous offspring of parents with type I diabetes: the German BABYDIAB study. Diabetologia 42:671–677CrossRefPubMed
14.
go back to reference Parikka V, Näntö-Salonen K, Saarinen M et al (2012) Early seroconversion and rapidly increasing autoantibody concentrations predict prepubertal manifestation of type 1 diabetes in children at genetic risk. Diabetologia 55:1926–1936CrossRefPubMed Parikka V, Näntö-Salonen K, Saarinen M et al (2012) Early seroconversion and rapidly increasing autoantibody concentrations predict prepubertal manifestation of type 1 diabetes in children at genetic risk. Diabetologia 55:1926–1936CrossRefPubMed
15.
go back to reference Krischer JP, Lynch KF, Schatz DA et al (2015) The six-year incidence of diabetes associated autoantibodies in genetically at-risk children: the TEDDY study. Diabetologia 58:980–987CrossRefPubMed Krischer JP, Lynch KF, Schatz DA et al (2015) The six-year incidence of diabetes associated autoantibodies in genetically at-risk children: the TEDDY study. Diabetologia 58:980–987CrossRefPubMed
16.
go back to reference Walter M, Albert E, Conrad M et al (2003) IDDM2/insulin VNTR modifies risk conferred by IDDM1/HLA for development of Type 1 diabetes and associated autoimmunity. Diabetologia 46:712–720CrossRefPubMed Walter M, Albert E, Conrad M et al (2003) IDDM2/insulin VNTR modifies risk conferred by IDDM1/HLA for development of Type 1 diabetes and associated autoimmunity. Diabetologia 46:712–720CrossRefPubMed
17.
go back to reference Valdes AM, Erlich HA, Carlson J, Varney M, Moonsamy PV, Noble JA (2012) Use of class I and class II HLA loci for predicting age at onset of type 1 diabetes in multiple populations. Diabetologia 55:2394–2401PubMedCentralCrossRefPubMed Valdes AM, Erlich HA, Carlson J, Varney M, Moonsamy PV, Noble JA (2012) Use of class I and class II HLA loci for predicting age at onset of type 1 diabetes in multiple populations. Diabetologia 55:2394–2401PubMedCentralCrossRefPubMed
18.
go back to reference Awa WL, Boehm BO, Kapellen T et al (2010) HLA-DR genotypes influence age at disease onset in children and juveniles with type 1 diabetes mellitus. Eur J Endocrinol 163:97–104CrossRefPubMed Awa WL, Boehm BO, Kapellen T et al (2010) HLA-DR genotypes influence age at disease onset in children and juveniles with type 1 diabetes mellitus. Eur J Endocrinol 163:97–104CrossRefPubMed
19.
go back to reference Williams AJK, Lampasona V, Schlosser M et al (2015) Detection of antibodies directed to the N-terminal region of GAD is dependent on assay format and contributes to differences in the specificity of GAD autoantibody assays for type 1 diabetes. Diabetes. doi:10.2337/db14-1693 Williams AJK, Lampasona V, Schlosser M et al (2015) Detection of antibodies directed to the N-terminal region of GAD is dependent on assay format and contributes to differences in the specificity of GAD autoantibody assays for type 1 diabetes. Diabetes. doi:10.​2337/​db14-1693
Metadata
Title
Islet autoantibody phenotypes and incidence in children at increased risk for type 1 diabetes
Authors
Eleni Z. Giannopoulou
Christiane Winkler
Ruth Chmiel
Claudia Matzke
Marlon Scholz
Andreas Beyerlein
Peter Achenbach
Ezio Bonifacio
Anette-G. Ziegler
Publication date
01-10-2015
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 10/2015
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-015-3672-y

Other articles of this Issue 10/2015

Diabetologia 10/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.